Skip to main content
Sister Publication Links
  • ESG: THE IMPLEMENTATION IMPERATIVE
Subscribe
  • Sign Up Free
  • Login
  • Subscribe
  • News
    • Current News
    • Providers
    • Insurance
    • Digital Health
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Transformation
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Unwell in America
  • Opinion
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top 25 Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Digital Health Transformation Summit
    • ESG: The Implementation Imperative Summit
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Hospital at Home
    • - Workplace of the Future
    • - Digital Health
    • - Future of Staffing
    • - Hospital of the Future (Fall)
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
  • Data Center
    • Data Center Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • MORE+
    • Contact Us
    • Advertise
    • Media Kit
    • Newsletters
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Government
November 29, 2017 12:00 AM

FDA to pave clearer path for generic drugs

Alex Kacik
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print

    U.S. FDA Commissioner Dr. Scott Gottlieb relayed a new guidance Tuesday that may shed some light on the path generic-drug manufacturers can take to get their products to market.

    The Food and Drug Administration aims to make it easier for generic-pharmaceutical developers to plan how they can copy complex drugs, which should ultimately lower pharmaceutical prices when more of the cheaper drugs enter the market.

    Certain drugs have been difficult to replicate and gain regulatory approval for, particularly drug-device combinations like EpiPen, because there has been minimal guidance from the FDA on how to adequately do so. The agency has committed to explaining how to copy complex drugs at least two years in advance of the first potential generic entrant, Gottlieb said Tuesday during the FDA's Generic Drug Science Day in White Oak, Md.

    The generic applicant will be approved, even if there are differences in labeling, as long as the manufacturer can demonstrate that the differences between its drug and the branded model do not affect the clinical effect or safety, he said.

    More clarity would help more generics get to market, which would lower drug prices, said Scott Knoer, chief pharmacy officer for the Cleveland Clinic system. This would benefit consumers, providers and insurers that have had to find workarounds to drugs that have ballooned in price, he said.

    Generic manufacturers have essentially been "shooting in the dark" because the FDA did not provide guidance on the scientific principles to prove sameness in cases like the EpiPen auto-injector delivery mechanism, Knoer said.

    "It will give generic manufacturers a head start on meeting regulatory requirements," said Knoer, adding that it should have a tangible effect on certain products.

    While the guidance provides some flexibility in evaluating drugs that face roadblocks to market, there is some gray area in defining how much generics can vary, said David Rosen, a former FDA official and current head of the FDA regulatory practice group at the law firm Foley & Lardner.

    "How much generic drugs can vary and not affect the clinical effect or safety profile remains to be seen," he said. "We have to make sure we do things that are in the best interest of the patients."

    Still, facilitating more communication between drug manufacturers and the FDA is a good thing, Rosen added.

    Gottlieb and other healthcare policy experts have been pushing for more low-cost generic-drug approvals as a means to lower pharmaceutical prices. The FDA has published a list of off-patent branded drugs without approved generics in response to some companies that have hiked the price of decades-old off-patent drugs that had minimal competitors. The agency has pledged to prioritize certain generic-drug applications for branded drugs that have less than three competitors, and it also aims to clear the existing orphan drug request backlog and streamline the response process.

    Their efforts, coupled with the renewal of the Generic Drug User Fee Act, have seemingly paid off. The FDA approved 763 generic drugs in fiscal 2017, setting the mark for the most approved in a single year, outpacing last year's record high by 112 generic approvals, according to the agency's 2017 generic drugs activities report.

    Prices typically fall more significantly when there are multiple generic alternatives on the market, according to the FDA. While the first generic competitor typically only prices its product slightly lower than its brand-name counterpart, the price is cut to nearly half when there are two generics on the market, the agency said.

    Public outcry erupted when Mylan bought the rights to EpiPens and increased the injectors' list price nearly 550% to more than $600. Valeant Pharmaceuticals pulled a similar stunt when it acquired the heart drugs nitroprusside and isoproterenol, which are widely used in hospitals nationwide, and raised prices over 30-fold and 70-fold, respectively, over a three-year span. Nearly two dozen companies have since been accused of price-fixing and manipulating markets in a civil probe by a number of U.S. states.

    Although the main ingredient in the EpiPen, epinephrine, had been available for years and was not patent protected, generic competitors had trouble passing regulatory muster with an adequate copy.

    "We still don't have a generic version of conjugated estrogen, and we've had some products like an enoxaparin generic that took some time," Rosen said. "Anything we can do to facilitate that stuff helps."

    While the new guidance will help stop drug companies from blocking approval of copies, which Mylan did with generic EpiPens' device components, new products backed by lower-budget companies will still have an uphill battle to gain market share, said Erin Fox, who directs the Drug Information Center at University of Utah Health.

    "Brand-name companies will be able to market their product as 'better' because it doesn't work exactly the same," she said.

    One key element will be if the FDA approves these generics as interchangeable, experts said. If they aren't, pharmacists could only substitute a lower-cost product at the pharmacy with the doctor's approval.

    "If the FDA allows approval of such products and certifies them as interchangeable, it will help expand competition and promote timely access to safe, effective lower-cost drugs," said Ameet Sarpatwari, assistant director of the program on regulation, therapeutics and law at Brigham and Women's Hospital and Harvard Medical School.

    Some are still concerned that branded-drug manufacturers will be able to elude competition by manipulating patent and regulatory loopholes. Branded-drug manufacturers have overwhelmed generic competitors with an onslaught of patent infringement lawsuits and have denied them the samples needed to replicate their drugs to stall perceived threats.

    Allergan took the uncharted approach of transferring the patents on its $1.4 billion eye drug Restasis to the St. Regis Mohawk Tribe, on the theory that the tribe's sovereign immunity protects the drug from generic competitors. A U.S. District Court has since ruled the patents invalid.

    "We have to make sure, when a company is filing as many late-stage patents as they are, that there's heightened scrutiny associated with it," Chip Davis, president and CEO of the Association for Accessible Medicines, the trade association for manufacturers and distributors of generic prescription drugs, told Modern Healthcare in October.

    Manufacturers' "anticompetitive creativity fueled by their flagrantly aggressive pricing strategies" is astounding, Cleveland Clinic's Knoer said.

    "It's like whack-a-mole," he said. "Just when you solve one problem, a different one pops up."

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    Abortion clinic
    Idaho hospital halts obstetrical care as abortion laws become stricter
    mh_20160711p29_bills_i.jpg
    State, local governments pay off medical debt relief with COVID funds
    Most Popular
    1
    More healthcare organizations at risk of credit default, Moody's says
    2
    Centene fills out senior executive team with new president, COO
    3
    SCAN, CareOregon plan to merge into the HealthRight Group
    4
    Blue Cross Blue Shield of Michigan unveils big push that lets physicians take on risk, reap rewards
    5
    Bright Health weighs reverse stock split as delisting looms
    Sponsored Content
    Modern Healthcare Alert: Sign up for this breaking news email to be kept in the loop as urgent healthcare business news unfolds.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2023. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • Providers
      • Insurance
      • Digital Health
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Unwell in America
    • Opinion
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top 25 Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Digital Health Transformation Summit
        • ESG: The Implementation Imperative Summit
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Hospital at Home
        • - Workplace of the Future
        • - Digital Health
        • - Future of Staffing
        • - Hospital of the Future (Fall)
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • Data Center
      • Data Center Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • MORE+
      • Contact Us
      • Advertise
      • Media Kit
      • Newsletters
      • Jobs
      • People on the Move
      • Reprints & Licensing